Stocktoria
Dare Bioscience, Inc. DARE
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 2014-04-10
Dare Bioscience, Inc. statistics & valuation
Market cap as of 2026-06-29. Multiples are price-derived and refreshed daily; everything else is from filings.
Key ratios (by fiscal year)
| Ratio | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Operating margin | -1315.5% | -239692.2% | -1101.9% | -313.9% | — |
| Net margin | -1300.7% | -41430.9% | -1074.2% | -309.5% | — |
| FCF margin | -998.4% | 50087.0% | -1407.8% | -181.6% | — |
| Return on assets | -41.3% | -18.3% | -141.7% | -70.6% | -69.3% |
| Return on equity | -471.4% | 67.4% | 597.5% | -278.5% | -99.8% |
| Current ratio | 1.14 | 0.85 | 0.86 | 1.36 | 3.44 |
| Revenue growth | 10429.4% | -99.7% | -71.9% | — | — |
Source: SEC EDGAR filings · CIK 0001401914 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.